About:

Pharmaero develops inhalation products based on the ADI; a soft mist inhaler. The device delivers accurate dosing to the lungs for systemic as well as local treatment. Pharmaero was founded in 2009.

Ownership:

Pharmaero Aps is a 50:50 joint venture between Scandinavian Health Limited (SHL), a significant player in the injectable device space, and Xellia Pharmaceuticals ApS, a prominent API and FDF supplier.